| Adverse event |
Study |
Paroxetine |
Comparator |
Odds Ratio, Random [95% CI] |
NNTh [95% CI] |
| Events |
Total |
Events |
Total |
| Paroxetine versus older antidepressants |
|
| Paroxetine vs amitriptyline |
|
| Anticholinergic |
Hutchinson 1992; Staner 1995
|
5 |
79 |
12 |
51 |
0.22 [0.07 to 0.76] |
6 [3 to 23] |
| Body as a whole |
29060/281 PAR; PAR MDUK 032
|
54 |
111 |
37 |
110 |
1.87 [1.08 to 3.23] |
7 [4 to 46] |
| Dizziness |
29060/299; 29060.07.001; Hutchinson 1992; Kuhs 1989; Laursen 1985; Sacchetti 2002; SER‐CHN‐1
|
31 |
398 |
57 |
379 |
0.42 [0.25 to 0.72] |
14 [9 to 36] |
| Behaviour (irritability) |
Battegay 1985 |
7 |
11 |
1 |
10 |
15.75 [1.42 to 174.25] |
2 [1 to 5] |
| Palpitations |
Battegay 1985; Bignamini 1992; Laursen 1985
|
4 |
188 |
13 |
186 |
0.42 [0.06 to 2.74] |
21 [11 to 152] |
| Tachycardia |
Sacchetti 2002; SER‐CHN‐1
|
6 |
177 |
21 |
183 |
0.43 [0.04 to 4.44] |
12 [7 to 36] |
| Tremor |
29060/299; 29060.07.001; Battegay 1985; Geretsegger 1995; Laursen 1985; Sacchetti 2002; SER‐CHN‐1; Staner 1995; Stuppaeck 1994
|
25 |
508 |
53 |
506 |
0.44 [0.22 to 0.90] |
18 [11 to 44] |
| Paroxetine vs clomipramine |
|
| Anticholinergic |
Guillibert 1989 |
7 |
40 |
16 |
39 |
0.30 [0.11 to 0.86] |
4 [2 to 24] |
| Paroxetine vs dothiepin |
|
| Headache |
29060/056/UK; Dunner 1992
|
39 |
203 |
18 |
202 |
2.46 [1.35 to 4.48] |
10 [6 to 28] |
| Paroxetine vs imipramine |
|
| Dyspnea |
29060/409 |
4 |
38 |
12 |
37 |
0.25 [0.07 to 0.85] |
5 [3 to 25] |
| Sweating |
Cohn 1990; Feighner 1989; Peselow 1989; Shrivastava 1992;029060/1/CPMS‐095; Fabre 1992; Ohrberg 1992
|
61 |
373 |
97 |
308 |
0.43 [0.29 to 0.65] |
7 [5 to 11] |
| Weight gain |
Ohrberg 1992 |
1 |
79 |
8 |
80 |
0.12 [0.01 to 0.95] |
11 [6 to 58] |
| Paroxetine vs maprotiline |
|
| Appetite decreased |
Szegedi 1995 |
12 |
145 |
2 |
153 |
6.81 [1.50 to 30.99] |
14 [8 to 47] |
| Headache |
29060.065.BE; Schnyder 1996; Szegedi 1995
|
51 |
210 |
30 |
209 |
1.96 [1.13 to 3.39] |
10 [6 to 41] |
| Weight gain |
29060.065.BE; Schnyder 1996
|
0 |
65 |
8 |
66 |
0.10 [0.01 to 0.81] |
8 [5 to 24] |
| Paroxetine vs mianserin |
|
| Nervous system |
29060/III/85/030; Dorman 1992
|
15 |
47 |
25 |
43 |
0.25 [0.09 to 0.67] |
4 [2 to 16] |
| Gastrointestinal |
29060/III/83/022; 29060/III/85/030;Dorman 1992
|
32 |
65 |
13 |
61 |
3.56 [1.63 to 7.79] |
4 [2 to 8] |
| Paroxetine versus other SSRIs |
|
| Paroxetine vs fluoxetine |
|
| Dizziness |
29060/356; Gagiano 1993; Geretsegger 1994; MY‐1045/BRL‐029060/1; Ontiveros 1994
|
114 |
868 |
81 |
869 |
1.50 [1.11 to 2.04] |
26 [15 to 118] |
| Fatigue |
29060/356 |
2 |
68 |
9 |
70 |
0.21 [0.04 to 0.99] |
10 [5 to 90] |
| Nervous system |
Cassano 2002; De Wilde 1993
|
24 |
173 |
47 |
169 |
0.41 [0.24 to 0.72] |
7 [4 to 18] |
| Sexual problems (ejaculation disorders) |
MY‐1045/BRL‐029060/1 |
36 |
357 |
12 |
351 |
3.17 [1.62 to 6.20] |
15 [10 to 33] |
| Paroxetine vs fluvoxamine |
|
| Sweating |
Kiev 1997 |
10 |
30 |
3 |
30 |
4.50 [1.09 to 18.50] |
4 [2 to 30] |
| Paroxetine vs sertraline |
|
| Fatigue |
Aberg‐Wistedt 2000; Fava 2002
|
97 |
273 |
48 |
272 |
2.41 [1.21 to 4.77] |
6 [4 to 9] |
| Sexual problems (ejaculation disorders) |
Aberg‐Wistedt 2000; Fava 2002
|
32 |
273 |
10 |
272 |
3.50 [1.68 to 7.28] |
12 [8 to 28] |
| Tremor |
Aberg‐Wistedt 2000; Fava 2002
|
42 |
273 |
25 |
272 |
1.82 [1.07 to 3.09] |
16 [9 to 142] |
|
Paroxetine versus newer or non‐conventional antidepressants and other agents
|
|
| Paroxetine vs aprepitant |
|
| Sexual problems (ejaculation disorders) |
Kramer 1998 |
14 |
72 |
2 |
71 |
8.33 [1.82 to 38.16] |
6 [4 to 15] |
| Paroxetine vs hypericum |
|
| Dizziness |
Szegedi 2005 |
24 |
126 |
9 |
125 |
3.03 [1.35 to 6.82] |
8 [5 to 2]8 |
| Paroxetine vs mirtazapine |
|
| Fatigue |
Benkert 1999; Schatzberg 2002; Wade 2003
|
33 |
360 |
54 |
366 |
0.47 [0.22 to 0.99] |
12 [7 to 43] |
| Flatulence |
Schatzberg 2002 |
15 |
126 |
4 |
128 |
4.19 [1.35 to 13.00] |
11 [7 to 42] |
| Headache |
Benkert 1999; Schatzberg 2002; Wade 2003
|
73 |
360 |
46 |
366 |
1.77 [1.12 to 2.79] |
11 [7 to 28] |
| Sexual problems (general) |
Benkert 1999 |
18 |
136 |
4 |
139 |
5.15 [1.69 to 15.64] |
10 [6 to 25] |
| Sweating |
Benkert 1999; Schatzberg 2002; Wade 2003
|
38 |
360 |
13 |
366 |
3.12 [1.61 to 6.03] |
14 [9 to 30] |
| Tremor |
Benkert 1999; Schatzberg 2002
|
21 |
262 |
6 |
267 |
3.67 [1.43 to 9.42] |
17 [11 to 49] |
| Weight gain |
Benkert 1999; Schatzberg 2002; Wade 2003
|
12 |
360 |
46 |
366 |
0.25 [0.13 to 0.47] |
11 [8 to 19] |
| Paroxetine vs nefazodone |
|
| Sweating |
Hicks 2002 |
7 |
20 |
0 |
20 |
22.78 [1.20 to 432.58] |
3 [2 to 7] |
| Paroxetine vs reboxetine |
|
| Asthenia |
Gallen 2001; M/2020/0047; M/2020/0052
|
91 |
693 |
48 |
682 |
2.01 [1.39 to 2.91] |
16 [11 to 34] |
| Chills |
Gallen 2001; M/2020/0047; M/2020/0052
|
13 |
693 |
36 |
682 |
0.34 [0.18 to 0.65] |
29 [19 to 69] |
| Dyspnea |
M/2020/0047; M/2020/0052
|
13 |
428 |
3 |
417 |
4.32 [1.22 to 15.31] |
43 [24 to 200] |
| Paraesthesia |
Gallen 2001; M/2020/0047; M/2020/0052
|
10 |
693 |
22 |
682 |
0.44 [0.20 to 0.96] |
56 [30 to 535] |
| Sexual problems (anorgasmia) |
Gallen 2001; M/2020/0047; M/2020/0052
|
24 |
693 |
1 |
682 |
9.84 [2.23 to 43.46] |
30 [21 to 52] |
| Sexual problems (libido decreased) |
Gallen 2001; M/2020/0047; M/2020/0052
|
26 |
693 |
11 |
682 |
2.34 [1.14 to 4.82] |
47 [26 to 229] |
| Sleep disorders |
Gallen 2001; M/2020/0047; M/2020/0052
|
16 |
693 |
4 |
682 |
3.67 [1.29 to 10.45] |
58 [34 to 215] |
| Sweating |
Gallen 2001; M/2020/0047; M/2020/0052
|
55 |
693 |
104 |
682 |
0.48 [0.34 to 0.68] |
14 [9 to 25] |
| Tremor |
Gallen 2001; M/2020/0047; M/2020/0052
|
31 |
693 |
11 |
682 |
2.75 [1.35 to 5.57] |
35 [21 to 95] |
| Weight gain |
Gallen 2001; M/2020/0052
|
10 |
431 |
2 |
424 |
4.12 [1.02 to 16.62] |
54 [29 to 351] |
| Yawning |
Gallen 2001;M/2020/0047
|
11 |
527 |
0 |
523 |
12.13 [1.57 to 93.64] |
48 [30 to 115] |
| Paroxetine vs tianeptine |
|
| Dizziness |
Lepine 2001; Waintraub 2002
|
10 |
304 |
1 |
300 |
7.02 [1.25 to 39.32] |
34 [20 to 118] |
